OSAAI 2025 Northwest Allergy Forum (OSAAI NWAF)

Portland, OR US
October 3, 2025 to October 5, 2025

The OSAAI 2025 Northwest Allergy Forum offers an outstanding lineup of expert speakers covering a diverse range of topics.  This is an incredible chance to gain the latest insights and developments in areas such as food allergy, primary and secondary immunodeficiency, the impact of climate change on AD, and cutting-edge research.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Oregon Society of Allergy, Asthma and Immunology (OSAAI). The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 9 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 9 contact hours.

No commerical support was received for this activity.

Target Audience

Practicing allergists
Allied healthcare professionals

Learning Objectives

At the conclusion of this activity, attendees should be able to:

1.   Analyze recent studies on the diagnosis and treatment of food allergies
2.   Describe the manifestations of immune deficiencies and how to distinguish these immune defects
3.   Revew the treatments used for primary immunodeficiency
4.   Discuss the pipeline of biologics in asthma
5.   Evaluate and select evolving therapeutic strategies
6.   Review mechanisms, current bioloigics and effects
7.   Evaluate current clinical data indicating suggesting possible remittive effects of biologics in asthma
8.   Recognize various presentations of contact dermatitis
9.   Examine the role of patch testing and practical aspects of emerging and important allergens
10. Recognize rashes seen in the allergy office but aren’t allergic
11. Detect some differentiating features of eczematous diseases

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Attendance
  • 9.00 CBRN
Course opens: 
10/03/2025
Course expires: 
12/31/2025
Event starts: 
10/03/2025 - 6:00pm CDT
Event ends: 
10/05/2025 - 1:00pm CDT
Add to calendar: 
Rating: 
0

OSAAI 2025: Northwest Allergy Forum
October 3-5, 2025
Hyatt Regency, Portland, OR 

All Education Sessions to be held in Deschutes Ballroom A
Exhibits and Coffee Breaks to be held Deschutes Ballroom B-C

PROGRAM

Friday, October 3     

5:00pm-6:00pm     Registration, Exhibits & Welcome Reception    

6:00pm-7:00pm    AI in Allergy / Q&A  | Jay Portnoy, MD
Friday AI in Allergy, featuring Dr. Jay Portnoy, is brought to you by the California Society of Allergy, Asthma and Immunology and the American College of Allergy, Asthma & Immunology

Saturday, October 4

6:45am-7:50am    Exhibits, Registration, Coffee Break

7:50am-8:00am    Welcome & Introduction – Melanie Wayne, MSN, FNP-BC – President, OSAAI
Session Moderator – Melanie Wayne, MSN, FNP-BC

8:00am-9:00am     Venom Hypersensitivity / Q&A | Jeffrey Demain, MD        

9:00am-10:00am     Eosinophilia: Advances and Insights in Diagnosis and Management / Q&A | Princess Ogbogu, MD

10:00am-10:30am    Coffee Break | Exhibits | Posters

10:30-11:30am     Primary Immunodeficiency / Q&A | Antoine Azar, MD

11:30am-12:30pm    Implementing the Allergy Practice Parameters using AI / Q&A | Jay Portnoy, MD

12:30pm        Adjourn  

Sunday, October 5  

6:45am-7:50am    Coffee Break, Exhibits

7:50am-8:20am    OSAAI/WSSAAI Society Business Meetings

8:20am-8:30am    Welcome & Introduction
Session Moderator – Albert Tsien, MD - OSAAI Board of Directors

8:30am-9:30am        Food Allergy and OIT / Q&A | Jessica Macdougall, MD

9:30am-10:30am     Secondary Immunodeficiency / Q&A | Antoine Azar, MD

10:30am-11:00am     Coffee Break | Exhibits

11:00am-12:00pm    Climate Change and Impact on Atopic Disease / Q&A | Jeffrey Demain, MD

12:00pm-1:00pm     Eosinophilic Gastrointestinal Disorders: EoE and Beyond / Q&A | Princess Ogbogu, MD

1:00pm        Adjourn

Hyatt Regency Portland, OR
375 NE Holladay Street
Portland, OR 97232
United States

All relevant financial relationships with ineligible companies have been mitigated.

Antoine E. Azar, MD – Speaker
Advisor: Grifols
Consultant: ADMA, ArgenX, CSL Behring, Takeda
Researcher: ADMA, Grifols

Jeffrey G. Demain, MD – Speaker
Speaker: Blueprint

Princess Ogbogu, MD – Speaker 
Advisor: AstraZeneca
Researcher: AstraZeneca, DBV Technologies, Blueprint

The following have no relevant financial relationships with ineligible companies to disclose:

Jessica Macdougall, MD, MS – Speaker 
Jay Portnoy, MD – Speaker
Melanie Wayne, FNP – Planner, Moderator
James Baker, MD – Planner
Albert Tsien, MD – Planner
Karen Anstey, MD – Planner
Maxwell Li, MD – Planner
Karol Anderson - Planner

Available Credit

  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Attendance
  • 9.00 CBRN
Please login or create an account to take this course.